What Is AITL (Angioimmunoblastic T-cell) Lymphoma?

Angioimmunoblastic T-cell lymphoma, usually called AITL, is a rare and aggressive cancer of the immune system that arises from a specific type of white blood cell known as a T-follicular helper cell. It accounts for roughly 1 to 2 percent of all non-Hodgkin lymphomas but makes up about 15 to 20 percent of peripheral T-cell lymphomas, making it the second most common subtype in that broader category. AITL tends to strike older adults, often presents at an advanced stage, and can mimic infections or autoimmune diseases so closely that it is sometimes misdiagnosed for months.

Who Gets AITL and How Common Is It

AITL is diagnosed most often in people in their late sixties and seventies. Data from the U.S. Surveillance, Epidemiology, and End Results database put the average age at diagnosis at 69 years, and most people already have advanced-stage disease by the time they are diagnosed. The disease is slightly more common in Europe than in Asia or North America. That geographic difference may be partly explained by the higher rates of NK/T-cell lymphoma seen in Asian populations rather than a true excess of AITL cases in Europe.¹

One reason AITL tends to appear later in life is that it is closely tied to a process called age-related clonal hematopoiesis. As people age, their blood-forming stem cells can acquire genetic mutations and start producing dominant clones of cells. In AITL, early mutations in genes called TET2 and DNMT3A appear in those stem cells first. Additional mutations that drive the actual lymphoma, particularly one in a gene called RHOA, then arise in T-follicular helper cells that have already inherited those early changes.² A study of AITL patients found clonal-hematopoiesis-associated mutations in over 70 percent of cases, and those same mutations were shared across the T-cell lymphoma, accompanying myeloid cancers, or B-cell lymphomas that sometimes developed in the same patient. The study also found that tobacco smoking-associated mutational patterns were enriched among the later, lymphoma-driving mutations, suggesting smoking may contribute to disease development.³

How AITL Develops at the Genetic Level

AITL develops through a multi-step process of genetic damage. The earliest mutations affect genes that regulate how DNA is chemically modified, specifically TET2 and DNMT3A. These mutations show up not just in the tumor but also in normal blood cells of the same patient, confirming they originate in shared ancestral stem cells. What pushes the process from pre-cancerous clonal expansion to full-blown lymphoma is a second wave of mutations. The most characteristic is a mutation in the RHOA gene, which produces an altered protein called RHOA G17V. In one sequencing study, this RHOA mutation was present in about two-thirds of AITL samples tested. Mutations in IDH2 are also common and relatively specific to AITL among T-cell lymphomas.⁴

These mutations together cause T-follicular helper cells to multiply uncontrollably while also disrupting the normal architecture of lymph nodes. The malignant cells tend to cluster around a network of specialized blood vessels within the lymph node, giving the tissue a distinctive appearance under a microscope.⁵ But the cancer cells are only part of the picture. The tumor microenvironment in AITL is crowded with inflammatory cells, expanded networks of follicular dendritic cells, and Epstein-Barr virus (EBV)-infected B cells. This inflammatory milieu drives many of the symptoms and complications that make AITL so tricky to manage.

The Role of Epstein-Barr Virus

EBV, the virus best known for causing mononucleosis, is found in the lymph nodes of most AITL patients, though it resides primarily in bystander B cells rather than in the malignant T cells themselves. Research has shown an association between the amount of EBV and another herpesvirus, HHV6B, and the degree of tissue disruption in AITL, suggesting the viruses may actively contribute to the disease worsening over time.⁶

EBV’s presence is more than an incidental finding. In the immune-suppressed environment AITL creates, EBV-infected B cells can proliferate aggressively enough to spawn a second, entirely separate cancer: diffuse large B-cell lymphoma. Case reports describe patients who developed EBV-driven B-cell lymphomas in the skin or other sites after being diagnosed with AITL.⁷ Studies of these secondary B-cell tumors frequently detect both EBV and the MYC protein, suggesting that viral infection and MYC-driven growth cooperate in transforming the bystander B cells.⁸ This risk of a second malignancy is one of the features that sets AITL apart from most other lymphomas.

Symptoms and Why AITL Mimics Other Diseases

The typical presentation of AITL includes widespread lymph node swelling, fever, night sweats, weight loss, and a skin rash. Many patients also have an enlarged liver or spleen. These symptoms overlap so heavily with infections, autoimmune conditions, and other lymphomas that AITL frequently sends clinicians down the wrong diagnostic path. The immune chaos the disease creates is the source of the confusion: AITL produces an exaggerated inflammatory response and widespread immune dysregulation, with a particular tendency toward autoimmune phenomena and recurrent infections.⁹

Blood tests in AITL can look alarming and misleading in equal measure. Many patients have elevated immunoglobulin levels across multiple antibody classes, a condition called polyclonal hypergammaglobulinemia. They may also develop autoimmune hemolytic anemia, where the body’s immune system destroys its own red blood cells. In one documented case, a 44-year-old woman with AITL tested positive on a routine HIV screening test. The result turned out to be a false positive caused by the rampant autoimmune antibody production. After chemotherapy brought her AITL under control, both the autoimmune anemia and the false HIV result disappeared.¹⁰ False-positive serologies for other infections and elevated autoimmune markers are common enough in AITL that experienced hematologists treat them as diagnostic clues rather than separate problems.

The immune deficiency that accompanies AITL also makes patients vulnerable to opportunistic infections caused by bacteria, fungi, and viruses that a healthy immune system would easily handle. This susceptibility often worsens during treatment, when chemotherapy further suppresses immunity.

How AITL Is Diagnosed

Diagnosing AITL requires a tissue biopsy, usually from a lymph node, followed by careful examination under the microscope and a battery of special stains. The malignant T cells in AITL express a set of proteins associated with T-follicular helper cells. Pathologists use a panel of markers including CD10, BCL6, PD-1, CXCL13, and ICOS to confirm that the tumor has a T-follicular helper phenotype. Expression of at least two or three of these markers, in the right tissue context, supports the diagnosis.¹¹

Even with modern tools, AITL remains one of the harder lymphomas to diagnose. The malignant T cells often make up only a small fraction of the total cells in the biopsy, outnumbered by the inflammatory bystanders that flood the tissue. This can make it look more like a reactive lymph node swelling than a cancer. Autoimmune diseases such as lupus and rheumatoid arthritis can produce lymph node changes that closely resemble AITL histologically, adding another layer of diagnostic difficulty.¹² Molecular testing for the RHOA G17V mutation or IDH2 mutations can help clinch the diagnosis in ambiguous cases, since these mutations are highly characteristic of AITL.¹³

Treatment Approaches

The standard first-line treatment for AITL is combination chemotherapy, most commonly a regimen called CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or similar multi-drug protocols. In the broader category of peripheral T-cell lymphomas, a drug called brentuximab vedotin, which targets the CD30 protein on cancer cells, has been combined with chemotherapy with promising results. However, the benefit for AITL specifically appears more limited. Real-world data show that AITL patients treated with brentuximab vedotin-based regimens had lower complete response rates and shorter progression-free survival compared to other peripheral T-cell lymphoma subtypes.¹⁴ A study examining brentuximab vedotin-containing treatment for AITL found that while about 82 percent of patients who received it as first-line therapy achieved a complete response, the overall survival was similar regardless of whether brentuximab vedotin was included, at roughly 19 to 20 months for CD30-positive patients.¹⁵

For patients who respond well to initial chemotherapy, consolidation with autologous stem cell transplant, where the patient’s own stem cells are collected and reinfused after high-dose chemotherapy, is a common strategy to deepen and extend the remission. A large European registry analysis found three-year progression-free and overall survival rates of about 55 percent and 73 percent, respectively, for patients who underwent upfront transplant for peripheral T-cell lymphomas including AITL.¹⁶ Timing matters enormously. Patients transplanted while in their first complete remission had far better outcomes than those transplanted later. In one study, progression-free survival at four years was about 56 percent for patients in complete remission at the time of transplant, compared to 30 percent for those with only partial response and 23 percent for those with chemotherapy-resistant disease.¹⁷

When AITL Comes Back

Relapse is common with AITL, and options narrow when it happens. One class of drugs that has shown particular promise for relapsed or treatment-resistant AITL is the histone deacetylase (HDAC) inhibitors, which work by altering how genes are expressed in the cancer cells. Belinostat, an intravenous HDAC inhibitor, produced an overall response rate of about 46 percent in AITL patients who had already failed other treatments, with roughly 18 percent achieving a complete response. The median duration of response was close to 14 months, though overall survival was still limited to about 9 months.¹⁸

Romidepsin, another HDAC inhibitor given by infusion, has been used as maintenance therapy for AITL and can sometimes sustain long-term remissions. But it comes with gastrointestinal side effects that erode quality of life. A newer oral HDAC inhibitor called tucidinostat, approved for relapsed peripheral T-cell lymphoma in China and Japan, appears to cause fewer non-blood-related side effects such as nausea, vomiting, and fatigue. In at least one reported case, switching from romidepsin to tucidinostat as maintenance therapy improved a patient’s gastrointestinal symptoms while keeping the lymphoma controlled.¹⁹ For a disease that often requires long-term treatment, the differences in side-effect profiles between drugs in the same class can meaningfully affect daily life.

Because IDH2 mutations are relatively common in AITL, there is growing interest in repurposing drugs that already target mutant IDH2 in other cancers. Enasidenib, an IDH2 inhibitor approved for a form of acute myeloid leukemia, is being explored in early-phase clinical trials for AITL patients whose tumors carry the IDH2 mutation. This represents a genuinely mutation-targeted approach, which has been the missing piece in AITL therapy for years.

Prognosis and What Drives It

Overall, AITL carries a worse prognosis than many other lymphomas. A large international study developed a dedicated prognostic scoring system for AITL that identified three risk groups. Patients in the low-risk group had a five-year overall survival of about 63 percent, intermediate-risk patients about 54 percent, and high-risk patients only about 21 percent. This AITL-specific score outperformed older, more general lymphoma prognostic tools.²⁰ The factors that push someone toward the high-risk end include older age, fever, poor physical fitness, anemia, and low albumin levels in the blood.²¹

The five-year numbers can feel discouraging, but they represent averages across all patients, including many who are elderly and have other health problems. Younger, fitter patients who achieve a complete response and proceed to stem cell transplant do substantially better than the overall averages suggest.

Tracking the Disease With Circulating Tumor DNA

One of the more interesting developments in AITL care is the use of circulating tumor DNA (ctDNA), fragments of cancer DNA that leak into the bloodstream, as a way to monitor how the disease is responding to treatment. Because AITL has such a strong and consistent molecular signature, researchers have found it particularly well suited for this kind of liquid biopsy approach.

In a study of 12 AITL patients, somatic mutations detectable in blood closely matched those found in tumor tissue biopsies. When patients achieved a complete metabolic response on imaging, all IDH2 and RHOA mutations that had been detectable in their blood before treatment disappeared. TET2 and DNMT3A mutations, however, often persisted even in patients whose scans looked clean. This makes biological sense: TET2 and DNMT3A mutations arise early, in blood stem cells that may survive treatment, while IDH2 and RHOA mutations are more specific to the actual lymphoma cells. The implication is that tracking IDH2 and RHOA variants in the blood may give a more accurate picture of whether the lymphoma itself is truly gone.²²

Broader research in peripheral T-cell lymphomas has found that the degree of ctDNA reduction after treatment correlates with relapse risk. Patients whose ctDNA levels dropped by at least 1.5 log units between baseline and the end of treatment had significantly better survival outcomes than those with smaller reductions.²³ If validated in larger studies, ctDNA monitoring could eventually help doctors decide earlier whether a treatment is working or whether a switch is needed, sparing patients weeks of ineffective and toxic therapy.

Living With AITL and Infection Risk

The immune dysfunction in AITL is not just a laboratory curiosity. It translates into real, day-to-day vulnerability. The disease was originally classified as an immune-dysplastic syndrome before being recognized as a true lymphoma, and that early label captured something real about the patient experience. People with AITL are prone to bacterial, fungal, and opportunistic infections because their immune system is fundamentally compromised by the disease itself, even before treatment begins. Chemotherapy and stem cell transplant compound the problem. Infection is a leading cause of morbidity and death in AITL patients, and aggressive prophylaxis and monitoring for infectious complications are standard parts of care.

The autoimmune phenomena, including rashes, joint pain, autoimmune blood cell destruction, and abnormal antibody production, can persist or flare throughout the disease course. Some patients find that these symptoms are as debilitating as the lymphoma itself. Treatment that controls the lymphoma usually improves the autoimmune problems as well, but not always completely, and the autoimmune features occasionally linger even when the cancer appears to be in remission.